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Abstract
Background: EPH (erythropoietin-producing hepatocellular) receptors are clinically relevant targets in several
malignancies. This report describes the effects of GLPG1790, a new potent pan-EPH inhibitor, in human embryonal
rhabdomyosarcoma (ERMS) cell lines.
Methods: EPH-A2 and Ephrin-A1 mRNA expression was quantified by real-time PCR in 14 ERMS tumour samples and in
normal skeletal muscle (NSM). GLPG1790 effects were tested in RD and TE671 cell lines, two in vitro models of ERMS, by
performing flow cytometry analysis, Western blotting and immunofluorescence experiments. RNA interfering experiments were
performed to assess the role of specific EPH receptors. Radiations were delivered using an x-6 MV photon linear accelerator.
GLPG1790 (30 mg/kg) in vivo activity alone or in combination with irradiation (2 Gy) was determined in murine xenografts.
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Results: Our study showed, for the first time, a significant upregulation of EPH-A2 receptor and Ephrin-A1 ligand in
ERMS primary biopsies in comparison to NSM. GLPG1790 in vitro induced G1-growth arrest as demonstrated by Rb,
Cyclin A and Cyclin B1 decrease, as well as by p21 and p27 increment. GLPG1790 reduced migratory capacity and
clonogenic potential of ERMS cells, prevented rhabdosphere formation and downregulated CD133, CXCR4 and Nanog
stem cell markers. Drug treatment committed ERMS cells towards skeletal muscle differentiation by inducing a
myogenic-like phenotype and increasing MYOD1, Myogenin and MyHC levels. Furthermore, GLPG1790 significantly
radiosensitized ERMS cells by impairing the DNA double-strand break repair pathway. Silencing of both EPH-A2 and
EPH-B2, two receptors preferentially targeted by GLPG1790, closely matched the effects of the EPH pharmacological
inhibition. GLPG1790 and radiation combined treatments reduced tumour mass by 83% in mouse TE671 xenografts.
Conclusions: Taken together, our data suggest that altered EPH signalling plays a key role in ERMS development and
that its pharmacological inhibition might represent a potential therapeutic strategy to impair stemness and to rescue
myogenic program in ERMS cells.
Keywords: Rhabdomyosarcoma, GLPG1790, Ephrin, Cancer stem cell, Radiation therapy, Tumour xenografts
Background
Rhabdomyosarcoma (RMS), the most common soft tissue
sarcoma in childhood and adolescence, arises from undif-
ferentiated mesenchymal cells with developing skeletal
muscle features [1]. In this age range, RMS includes two
main histological varieties, the embryonal (ERMS) and the
alveolar (ARMS) subtypes, characterized by specific gen-
etic alterations [2–4]. Despite refinements in dose and
schedule of multimodality treatment, the 5-year overall
survival of patients with high-risk RMS remains < 30%,
thereby requiring the identification of novel targets for a
more effective therapeutic intervention [5].
EPH (erythropoietin-producing hepatocellular) pro-
teins are a large family of receptor tyrosine kinases
(RTKs), comprehending EPH-A and EPH-B receptors,
which respectively bind the cell/surface-associated pro-
tein ligands, Ephrin-A and Ephrin-B [6–8]. EPH/Ephrin
signalling represents a complex network of cell commu-
nications. “Forward” signalling, corresponding to the
prototypical RTK mode of signal transduction, triggers
the activation of signal transduction effectors, such as
Rho, Ras family GTPases and AKT/mTORC1. “Reverse”
signalling transduces through the Src family kinase acti-
vation [8, 9]. EPH/Ephrin network plays a key role in a
wide array of developmental processes, such as cardio-
vascular and skeletal development, axon guidance and
tissue patterning [10]. EPH-A/Ephrin-A signalling has
been shown to be essential in inducing myogenic differ-
entiation of myoblasts through the suppression of the
Ras/ERK1/2 cascade [11]. Due to their physiological im-
portance, alterations in EPH/Ephrin cascade play a cen-
tral role in the pathogenesis of several diseases [12],
such as cancer [13, 14], in which EPH expression levels
are frequently upregulated [13–15], with EPH-A2 and
EPH-B4 being the most widely over-expressed EPH re-
ceptors [13]. EPH/Ephrin role in cancer is complex by
interfering in tumour initiation, progression, neovascu-
larization, invasion and metastatization [16]. Further-
more, increasing evidence also indicates that EPH/
Ephrin signalling is involved in cancer stem cell self-
renewal, facilitating tumour heterogeneity, metastasis
and therapeutic resistance [17]. The role of EPH/Ephrin
signalling in RMS cells is still largely unknown.
Although a global upregulation of EPH-B receptors and
Ephrin-B ligands was previously found in RMS tumours
[18], the expression levels of EPH-A receptors and
Ephrin-A ligand as well as the effects of EPH/Ephrin
inhibition in RMS cell biology remain unclear.
Recent efforts to design small molecule inhibitors of
EPHs have generated encouraging preclinical and
clinical results [19, 20]. This study describes the in vitro
activity of GLPG1790, a novel small molecule that is able
to inhibit various EPH receptor kinases [21]. Indeed,
EPH-A2 levels were found to be significantly upregu-
lated in ERMS tumours and cell lines in comparison
with normal skeletal muscle (NSM). Treatment of ERMS
cell lines with GLPG1790 in vitro significantly inhibited
tumour cell growth, reduced the stem-like cell population
and promoted myogenic differentiation of surviving cells.
Furthermore, GLPG1790 was able to radiosensitize ERMS
cells by affecting the radiation-induced activation of the
DNA-repair mechanisms. At molecular levels, GLPG1790
inhibited MAPK and AKT signal transduction pathways,
two well-established major drivers of ERMS oncogenicity
[22–25]. Similar effects were obtained by silencing EPH-
A2 and/or EPH-B2, the principal EPH receptors targeted
by GPLG1790 [21], this suggesting the specificity of
GLPG1790 activity. These findings indicate that EPH/
Ephrin signalling is associated with ERMS development
and aggressiveness, and suggest that EPH/Ephrin targeting
might be a promising tool in ERMS treatment, as already
suggested for other cancer types.
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Methods
Patient clinical features
Fourteen ERMS primary tumour samples were obtained at
diagnosis before any treatment from children admitted to
the Department of Oncology at the Alder Hey Children’s
NHS Foundation Trust, Liverpool. Histopathological diag-
nosis was confirmed using immunohistochemistry. Details
of the patients are reported in Table 1.
Institutional written informed consent was obtained
from the patient’s parents or legal guardians. Control
RNA was extracted from normal skeletal muscle (NSM)
obtained from eight children undergoing surgery for
non-oncological conditions. The study underwent ethical
review and approval according to the local institutional
guidelines (Alder Hey Children’s NHS Foundation Trust
Ethics Committee, approval number 09/H1002/88).
RNA isolation and quantitative real-time PCR
Total RNA was isolated by tumour tissues ground under
liquid nitrogen using 1 ml of TRIzol LS reagent (Invitro-
gen, Carlsbad, CA) per 50–100 mg of sample according to
the manufacturer’s protocol. RNA concentration and pur-
ity were measured by NanoDrop 2000 (Thermo Fisher
Scientific, Inc., Waltham, MA). Total RNA (2 μg) was sub-
jected to reverse transcription with High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Foster
City, CA) according to the manufacturer’s instructions.
Quantitative real-time PCR (Q-PCR) for human EPH-A2
(Hs00171656) and Ephrin-A1 (Hs00358886) mRNAs was
performed using the specific TaqMan Real Time Gene Ex-
pression Assays (Applied Biosystems). Each sample was
run in triplicate, in at least two independent experiments,
on a StepOne Real Time System (Applied Biosystems)
machine. Transcript levels were normalized to the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA, used as endogenous control. Relative quantifica-
tion (RQ) of each mRNA in tumour samples in compari-
son to NSM was calculated by the comparative Ct method
(2-ΔΔCt), using the StepOne v2.3 software (Applied Biosys-
tems). RQmax and RQmin, which are the maximum and
minimum limits of the RQ values based on the standard
error of the mean ΔCt values at 95% confidence interval,
were used to plot error bars.
Cell lines and tumour sphere culture, pharmacological
and radiation treatment
The human ERMS RD and TE671 cell lines were
respectively obtained by American Type Culture Collec-
tion (Manassas, VA) and Interlab Cell Line Collection
(Genoa, Italy). Cell lines were maintained in high-
glucose Dulbecco’s modified Eagle’s medium supple-
mented with 10% foetal bovine serum (FBS), 1% v/v L-
glutamine, 100 μg/ml streptomycin and 100 U/ml peni-
cillin and grown at 37 °C in a humidified atmosphere of
5% CO2. DNA profiling using the GenePrint 10 System
(Promega Corporation, Madison, WI) was carried out to
authenticate cell cultures, comparing the DNA profile of
our cell cultures with those found in GenBank.
Sphere-forming cells were obtained and radiation
treatment performed as already described [22]. EPH
receptor inhibitor GLPG1790 was provided by
Galapagos NV [21], dissolved in DMSO and stored at
− 20 °C until use. Chemical structural data for
GLPG1790 will be published shortly.
Table 1 Clinicopathological features of the analysed tumour cases. Variables were categorized as follows: age at diagnosis (months),
gender, histological subtype, primary site and clinical stage
Case Age (months) Gender Histology Primary site Stage
ERMS1 63 Male Embryonal Abdominal 3
ERMS2 122 Male Embryonal Pelvis 3
ERMS3 61 Male Embryonal Bladder 3
ERMS4 45 Male Embryonal Trunk 3
ERMS12 18 Male Embryonal Bladder 3
ERMS13 40 Female Embryonal Retroperitoneum 2
ERMS20 60 Female Embryonal Pelvis 2
ERMS21 3 Male Embryonal Abdominal 3
ERMS23 37 Female Embryonal Vagina 2
ERMS27 22 Female Embryonal Calf 1
ERMS30 176 Male Embryonal Lower limb 4
ERMS43 17 Male Embryonal Bladder 2
ERMS44 39 Male Embryonal Paratesticular 1
ERMS50 22 Male Embryonal Infratemporal fossa 2
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Cell viability, proliferation assay and FACS analysis
Cells were seeded at a density of 105 cells/ml. After
attachment, cells were treated with the indicated doses
of GLPG1790 or DMSO for the indicated times. Cellular
viability was measured using the trypan-blue exclusion
assay (Life Technologies, Grand Island, NY) and the
Countess II Automated Cell Counter (ThermoFisher
Scientific, Waltham, MA). Data are expressed as average
of triplicate ± standard deviation (SD). FACS analysis
was performed as previously described [26]. Data were
analysed using ModFit 3.1 software (BD Biosciences).
Results were plotted as means ± SD of three separate
experiments, having three determinations per assay for
each experimental condition.
Transient transfection
RD and TE671 cells were seeded at 4 × 105 cells/well in
6-well plates; small interfering RNA (siRNA) against hu-
man EPH-A2 (EPH-A2siRNA, sc-29304 by Santa Cruz
Biotechnology, Dallas, TX) and/or EPH-A2 (EPH-
B2siRNA, sc-39949 by Santa Cruz Biotechnology) or
siRNA negative control (CTRsiRNA, sc-37007 by Santa
Cruz Biotechnology) were combined with RNAiMAX
(Invitrogen) and used at 60 nM final concentration;
EPH-A2siRNA and EPH-B2siRNA are a pool of three target
specific 19–25 nt siRNAs designed to specifically knock
down the targeted genes. All the experiments were
performed in proliferating growth medium, i.e. supple-
mented with 10% FBS.
Morphological assessment
An Axio Vert.A1 microscope (Carl Zeiss Microscopy,
Thornwood, NY), furnished with an AxioCam MRc5
camera (Carl Zeiss Microscopy), was used to observe
the morphological changes of the cells treated with
GLPG1790. Cells were photographed at 3 days post-
treatment using a ×20 magnification. Images were
analysed by using the ImageJ 1.47v software (http://
imagej.nih.gov/ij/).
Anchorage-dependent or anchorage-independent colony
formation and wound healing assays
For anchorage-dependent colony formation assays,
4 × 103 cells were plated in 6-well plates, treated or not
with GLPG1790 and cultured for 8 days. Colonies were
fixed in 100% methanol, stained with 1% crystal violet,
and photographed. To quantify colonies, crystal violet
was dissolved in 30% acetic acid in water for 15 min at
room temperature (rt) and absorbance was measured
using the Biochrom Libra S22 UV/VIS spectropho-
tometer (Biochrom, Berlin, Germany) at wavelength of
595 nm; 30% acetic acid in water was used as the
blank. Colony formation capacity in GLPG1790
treated in comparison to untreated cells was
calculated as follow: (ODuntreated − ODGLPG1790 /
ODuntreated) × 100%, having three determinations per
experiment. For colony forming in soft agar assays,
2 × 104 cells were resuspended in 4 ml of 0.33% spe-
cial Noble agar (Difco, Detroit, MI) and plated (6-well
plate) in growth medium-containing 0.5% soft agar.
Colonies were photographed 14 days after plating.
For wound healing assays, RD and TE671 cells were
plated in 6-well plates and incubated with or without
GLPG1790 for 24 h. On the following day, a sterile
pipette tip was used to scratch the cell monolayer (4–
5 parallel scratches/plate). Cells were washed with
PBS, photographed to mark scratched tracks, and
incubated for 24 additional hours to evaluate cell
migration into the injured areas. Wound healing was
quantified using ImageJ 1.47v software. Experiments
were carried out in triplicate.
Western blot and immunofluorescence assays
Total extracts were prepared using RIPA buffer, and
protein concentration was determined using the BCA
protein assay kit (ThermoFisher Scientific). Western blot
analyses were performed as already described [27] by
using the following primary antibodies: p21 (C-19), p27
(F-8), Cyclin A (BF683), Cyclin D1 (M-20), Cyclin B1
(H-20), Cyclin E (HE12), c-Myc (9E10), Rb (C-15), integ-
rin β1 (M-106), integrin β5 (H-96), phosphor-Src (H-3),
Src (5D10C4), DNMT3B (G-9), phospho-ERK1/2 (E-4),
ERK1/2 (C-14, positive also for ERK1), p38 (H-147),
phospho-JNK (G7), JNK (D2), phospho-AKT1/2/3-R
(Ser473), AKT1/2/3 (H-136), phospho-mTOR (Ser2448),
mTOR (H-266), Myogenin (F5D), phospho-ATM
(10H11.E12, Ser1981), ATM (H-248), DNA-PKcs (E-6),
H2AX (C-20), Nanog (H-155), EPH-A2 (C-3), EPH-B2
(2D12C6), Ephrin-A1 (A-5), Ephrin-B2 (C-20), Ki-67
(Ki-67) and α-Tubulin (TU-02) by Santa Cruz Biotech-
nology; MYOD1 (MAB3878) and MyHC (05–716) by
EMD Millipore Corporation (Billerica, MA); phospho-
p38 (Thr180/Tyr182)(9211), phospho-H2AX (Ser139)
(2577), and phospho-EPH-A2 (Ser897) (D9A1) by Cell
Signaling Technology (Danvers, MA); EPH-B (total
EPH-B proteins), phospho-EPH-B (Tyr317), phospho-
DNA-PKcs (Thr2609) (10B1), integrin αV (P2W7) and
integrin β3 (PM6/13) by AbCam (Cambridge, UK).
Appropriate horseradish peroxidase (HRP)-conjugated
secondary antibodies (Santa Cruz Biotechnology) were
used for 1 h at rt. Protein signals were detected using
Western Bright ECL kit (Advansta, Menlo Park, CA) ac-
cording to the manufacturer’s instructions and visualized
by ChemiDoc XRS+ (Bio-Rad, Hercules, CA). Densitom-
etry was performed to quantify changes in protein ex-
pression using the Image Lab5.1 software (Bio-Rad).
Expression and cellular localization of MyHC, MYOD1,
CycD1 and p21 were assessed by immunofluorescence
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experiments as previously described [28]. Experiments
were replicated twice.
In vivo experiments, GLPG1790 and radiation treatment
Female CD1-nu/nu mice, at 6 weeks of age, were pur-
chased from Charles River (Milan, Italy) and maintained
under the guidelines established by our institution (Uni-
versity of L’Aquila, Medical School and Science and
Technology School Board Regulations, complying with
the Italian government regulation n.116 January 27,
1992 for the use of laboratory animals). Before any
invasive manipulation, mice were anesthetized with a
mixture of ketamine (25 mg/ml) and xylazine (5 mg/ml).
For xenotransplants, exponentially growing TE671 cells
were detached by trypsin-EDTA, washed twice in PBS
and resuspended in saline solution at cell densities of
1 × 106/200 μl. Xenotransplants were established by s.c.
injecting in the leg of 45-day-old female nude CD1 mice
1 × 107 tumour cells [23]. Treatments started when
tumours reached a volume of 0.5–1 cm3.
GLPG1790 solution was prepared in 0.5% methylcellu-
lose. The GLPG1790 dose used in the study had already
been tested to be non-toxic to mice but effective in
inducing inhibition of Ephrin signalling. GLPG170 was
administered every day for 2 weeks and always before
RT. Mice were irradiated using an Elekta 6-MV photon
linear accelerator. Six fractions of 2 Gy were delivered at
alternative days for a total dose of 12 Gy. A dose rate of
1.5 Gy/min was used with a source-to-surface distance
(SSD) of 100 cm. Prior to irradiation, mice were anesthe-
tized and were protected from off-target radiation by a
3-mm lead shield. Before tumour inoculation, mice were
randomly assigned to four experimental groups. Each
group was composed of 10 mice. One control group
received 0.5% methylcellulose by oral gavage; one group
received GLPG1790 solution at the dose of 30 mg/kg;
one group received RT (six fractions of 2 Gy delivered
three times/week to a total dose of 12 Gy); one group re-
ceived GLPG1790 solution at the dose of 30 mg/kg and
RT (six fractions of 2 Gy delivered three times/week to a
total dose of 12 Gy) delivered 24 h after GLPG1790
treatment. Experiments were stopped 12 days after the
last irradiation, and mice were sacrificed by carbon diox-
ide inhalation. Tumours were directly frozen in liquid
nitrogen for protein analysis and biochemical evaluation.
The effects of different treatments on tumour growth
were evaluated as follows: (1) by measuring tumour
volume during and at the end of experiment (tumour
volume was assessed every 4 days measurement with a
Vernier calliper (length × width); the volume of the
tumour was expressed in cubic millimetre according to
the formulation 4/3π r3; (2) by measuring tumour weight
at the end of the experiments; and (3) by determining
the time to progression (TTP), tumour progression (TP)
defined as an increase of greater than 100% of tumour
volume respect to the baseline. Tumour pieces were ho-
mogenized by Precellys tissue homogenizer (Bertin In-
struments, Montigny-le-Bretonneux, F) for grinding
samples prior to protein analysis.
Statistical analysis
Data were expressed as mean ± standard deviation (SD)
of each condition. Statistical significance between groups
was assessed by Student’s t test, and probability (p)
values of less than 0.05 were accepted as significant.
Continuous variables were summarized as mean and SD
or as median and 95% CI for the median. For continuous
variables, statistical comparisons between control and
treated groups were established by carrying out the
Kruskal-Wallis Tests (a parametric one-way analysis of
variance for independent groups) or the Mann-Whitney
test (in the case of two independent groups). Dichotom-
ous variables were summarized by absolute and/or relative
frequencies. For dichotomous variables, statistical compar-
isons between control and treated groups were established
by carrying out the exact Fisher’s test. For multiple com-
parisons, the level of significance was corrected by multi-
plying the p value by the number of comparisons
performed (n) according to Bonferroni correction. TTP
was analysed by Kaplan-Meier curves and Gehan’s gener-
alized Wilcoxon test. When more than two survival
curves were compared, the Logrank test 10 for trend was
used. The non-parametric rank correlation analysis be-
tween EPH-A2 or Ephrin-A1 mRNA levels and sex or dis-
ease stage was performed by determining the Spearman’s
and Kendall rank correlation coefficients. To assess the
probability that there is a trend in survival scores across
the groups, p values < 0.05 were considered statistically
significant. All tests were two-sided and were determined
by Monte Carlo significance. The effects of the treatments
were examined as previously described by Prewett et al.
[29]. The effect on tumour growth was measured by tak-
ing the mean tumour volume on day 24 for the different
treatment groups: controls, treatment with RT (treatment
a), treatment with GLPG1790 (treatment b) and treatment
with RT + GLPG1790 (treatment a + b). For tumour vol-
ume assessment, fractional tumour volume (FTV) for
each treatment group was calculated as the ratio between
the mean tumour volumes of treated and untreated tu-
mours. For tumour progression, fractional TTP (FTTP)
for each treatment group was calculated as the ratio be-
tween the median TTP of untreated and treated tumours.
This was done for treatment a, for treatment b and for
treatment a + b. The expected FTV or FTTP for the << a
+ b >> combination was defined as FTVa observed X
FTVb observed or as FTTPa-observed X FTTP observed.
The ratio FTV a + b expected/ FTV a + b observed or
FTTP a + b expected/FTTP a + b observed was the
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combination index (CI). If CI > 1, there are supra-additive
effects and if CI < 1 infra-additive ones. Strictly additive ef-
fects were observed if CI = 1. All statistical analyses were
performed using the SPSS® statistical analysis software
package, version 10.0.
Results
EPH-A2 and EPH-B signalling status in ERMS tumours and
cell lines
EPH-A2 and EPH-B have been shown to be the EPH
receptors most widely overexpressed in cancer [13].
a
b
c
Fig. 1 Expression and activation status of EPH-A2, EPH-B and related Ephrin ligands in ERMS tumours and cell lines. a EPH-A2 and b Ephrin-A1
transcript levels in 14 ERMS primary tumours and NSM, as measured by Q-PCR assays. GAPDH mRNA was used as an endogenous control. The
relative mRNA expression levels are presented as the average fold changes (RQ) in tumour biopsies vs. NSM, set at 1. Error bars represent the
RQmax and RQmin values of at least two independent assays, each performed in triplicate. c Western blots showing the expression levels of EPH-
A2, EPH-B, Ephrin-A1 and Ephrin-B2 proteins as well as the phosphorylation status of EPH-A2 (p-EPH-A2) and EPH-B (p-EPH-B) in RD and TE671
cell lines in comparison to NSM; α-Tubulin was used as loading control. Representative images of three different experiments
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Upregulation of EPH-B receptors and Ephrin-B-related
ligands has been found in RMS cells [18], whilst no data
have yet been reported for EPH-A2- and Ephrin-A1-
related ligand. The analysis of EPH-A2 and Ephrin-A1
transcript levels, performed in 14 ERMS primary tu-
mours by using Real Time PCR, showed that both tran-
scripts were significantly upregulated in all tumour
samples in comparison to NSM (Fig. 1a, b). No statisti-
cally significant correlations were found between EPH-
A2 or Ephrin-A1 mRNA levels and gender or disease
stage (EPH-A2 vs. gender: K-Tau = 0.0331, p = 0.9342,
CI = − 0.439 to 0.516; EPH-A2 vs. stage: r = −0.0164,
p = 0.9555, CI − 0.542 to 0.519; Ephrin-A1 vs. gender:
K-Tau = 0.0341, p = 0.9323, CI = − 0.471 to 0.472;
Ephrin-A1 vs. stage: r = 0.164, p = 0.5748, CI − 0.401 to
0.639. Western blot experiments revealed that protein
expression levels and/or phosphorylation status of EPH-
A2, EPH-B, Ephrin-A1 (EPH-A2-related ligand) and
Ephrin-B2 (EPH-B4-related ligand) were significantly
increased (p < 0.01) in ERMS cell lines in comparison to
NSM (Fig. 1c). Altogether, these results and the previ-
ously reported data [18] indicate that EPH/Ephrin
signalling is upregulated in ERMS.
GLPG1790 affects viability of ERMS cell lines
The effects of GLPG1790, a pan-EPH receptor kinase in-
hibitor [21], on RD and TE671 cell viability, were assessed
by trypan blue dye exclusion test: cells were treated for
48 h with increasing doses (0–50 μM) of GLPG1790. The
drug significantly (p < 0.01) decreased ERMS cell viability
in a dose-dependent manner, affecting on average the 50%
of the cellular viability at a dose of 3.5 μM on both cell
lines (Fig. 2a). Immunoblotting experiments showed that
in both ERMS cell lines, 3.5 μM GLPG1790 rapidly and
persistently decreased the activation/phosphorylation sta-
tus of EPH receptors, with a stronger action versus EPH-
A2 than EPH-B (Fig. 2b). The effects of 3.5 μM
GLPG1790 on ERMS proliferation rate and cell viability in
adherent or non-adherent (by using Poly-Hema-coated
plates) conditions were also investigated. In adherent con-
ditions, GLPG1790 rapidly (1 day) and persistently (1 day
to 6 days) inhibited tumour potential growth by
77.9 ± 4.9% on RD (p < 0.001) and 71.8 ± 5.1% on TE671
(p < 0.001) after 6 days of treatment (Fig. 2c, upper panel).
A statistically significant increase of death by 21.8 ± 5.3 in
RD (p < 0.001) and 17.3 ± 3.6 in TE671 (p < 0.001) was
detected only 1 day after treatment (Fig. 2c, lower panel).
In non-adherent conditions, GLPG1790 treatment drastic-
ally reduced the ability of RD and TE671 to grow in sus-
pension (Fig. 2d, upper panel) and resulted in almost total
cell death (Fig. 2d, lower panel). Notably, GLPG1790-
treated adherent cells exhibited a substantial change in
their morphology, with more elongated cellular bodies
already at 3 days post-exposure (Fig. 2e). Altogether, these
findings indicate that GLPG1790 has a dual action on
ERMS population by inducing both growth arrest (cyto-
static) and cytotoxic effects, which lead to a muscle-like
differentiated phenotype.
GLPG1790 induces G1 cell cycle growth arrest and reverts
ERMS transformed phenotype
Cell cycle distribution analysis, performed by flow
cytometry on ERMS cells treated for 24 h with 3.5 μM
GLPG1790, showed that this drug significantly reduced
DNA replication (26.2% ± 2.1 RD and 22.5% ± 3.5 TE671
of S phase) by primarily arresting cells in the G1 phase
(79.9% ± 4.7 RD and 86.6% ± 5.1 TE671) of the cell cycle,
as reported in Fig. 3a. Consistent with the G1 arrest,
GLPG1790 induced an early and persistent decrease of
Cyclin A (CycA) and Cyclin B1 (CycB1) expression levels
paralleled by the upregulation of p21 and p27 cell cycle in-
hibitors and by downshift of the retinoblastoma tumour
suppressor (Rb) (Fig. 3b), a master regulator of the G1-S
transition. Unexpectedly, GLPG1790 rapidly and persist-
ently upregulated the Cyclin D1 (CycD1) protein expres-
sion levels whilst no modulation of Cyclin E (CycE) and
c-Myc protein expression was observed (Fig. 3b). Immuno-
fluorescence experiments also confirmed that GLPG1790
increases the expression of CycD1 and p21, whose distri-
bution preferentially became nuclear (Fig. 3c). Then, the ef-
fects of 3.5 μM GLPG1970 on ERMS oncophenotype were
investigated. Eight days after treatment, GLPG1790
reduced the ERMS ability to form colonies in comparison
to untreated (DMSO) cells both in anchorage-dependent
(78% ± 3.2 for RD and 82.4% ± 0.76 for TE671) and
anchorage-independent (83.7% ± 6.1 for RD and
65.2% ± 2.1 for TE671) conditions (Fig. 4a, b, respectively).
GLPG1790 also reduced ERMS cell migration as assessed
by wound healing assays in which the same fields of con-
fluent cells were pictured immediately after the scratch
(time 0 h) and again after 24 h of GLPG1790 preincubation
(Fig. 4c, left panel). Drug treatment decreased the level of
wound closure to 37% for RD and 31% for TE671 of the
control sample (Fig. 4c, right panel). Then, we investigated
by Western blot analysis the GLPG1790 effects on the ex-
pression levels of integrins, which are involved in cell adhe-
sion and migration. Incubation with 3.5 μM GLPG1790
resulted in a decreased expression of integrin β1, β3 and
β5 but not of integrin αV (Fig. 4d). Collectively, these re-
sults suggest that the in vitro inhibition of EPH signalling
is able to affect ERMS transformed phenotype by reducing
cell substrate-dependent or cell substrate-independent pro-
liferation as well as cell migration.
GLPG1790 promotes myogenic differentiation and affects
the in vitro stem cell-like phenotype of ERMS cells
Since GLPG1790-induced changes in ERMS morphology
were suggestive of the acquisition of a myogenic-like
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phenotype, the expression of specific skeletal muscle
markers was evaluated by immunoblotting in ERMS
cells treated for 72 and 144 h with GLPG1790 in com-
parison to untreated control samples. As shown in
Fig. 5a, GLPG1790 induced a sustained increase of
MYOD1, Myogenin and MyHC protein levels in both
RD and TE671 cell lines. Notably, GLPG1790 reduced
DNMT3B protein (Fig. 5a), whose expression we have
a
c
e
b
d
Fig. 2 GLPG1790 decreases ERMS cell viability by inducing concomitant cell death and morphology changes in growth arrested cells. a Dose-dependent
effect of GLPG1790 on viability of RD and TE671 cells after 48 h of treatment. Cell viability was measured by trypan blue dye exclusion test. Results represent
the mean values of four independent experiments ±SD. b Cell lysates from ERMS cells untreated (DMSO) (−) or treated (+) with 3.5 μM GLPG1790 for the
indicated times were analysed by immunoblotting with specific antibodies for indicated proteins. Representative of four independent experiments. c RD and
TE671 cells, grown in adherent conditions, were treated with 3.5 μM GLPG1790 for the indicated times. Percentage of proliferating (upper panel) or dead
(lower panel) cells were obtained by trypan blue dye exclusion test. Results represent the mean values ± SD of four independent experiments. d RD and
TE671, cells grown in non-adherent conditions, were treated with 3.5 μM GLPG1790 for the indicated times. Percentage of proliferating (upper panel) or dead
(lower panel) cells were obtained by trypan blue dye exclusion test. Results represents the mean value of four independent experiments ±SD. e Cellular
morphology of ERMS cells untreated (DMSO) or treated with 3.5 μM GLPG1790 for 72 h was analysed under light microscope at ×20 magnification. In
GLPG1790 treated cells, more elongated cellular bodies were evident, many of which formed multinucleated myotube-like structures. Representative of three
independent experiments
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recently shown to restrain ERMS myogenic differenti-
ation [28]. In immunofluorescence experiments,
GLPG1790-treated cells displayed a myotube-like
morphology with a strong fluorescence signal of
MYOD1 and MyHC, this indicating that a proper myo-
genic differentiation was triggered by the pan-EPH in-
hibitor (Fig. 5b). The role of the EPH signalling in
maintaining the ERMS stem-like population phenotype
was also investigated. RD and TE671 cells were
cultured in stem cell medium (SC-medium) with or
without GLPG1790. Drug treatment drastically reduced
the rhabdosphere formation (Fig. 5c) as well as the per-
centage of CD133 positive cells by 95.6% ± 4.2 in RD
and 97.1% ± 6.1 in TE671, compared to the respective
SC-DMSO samples (Fig. 5d). A significant decrement
in the percentage of CXCR4 positive cells by
91.9% ± 7.7 in RD and 90.6% ± 8.2 in TE671 (Fig. 5e)
as well as a downregulation of Nanog protein levels
a
c
b
Fig. 3 GLPG1790 induces G1 growth arrest and related cell cycle protein modulation. a FACS analysis performed on ERMS cells untreated (DMSO) or
treated with 3.5 μM GLPG1790 for 24 h. Representative of three different experiments (upper panel). Histograms showing the percentage of cell cycle
phases in RD and TE671 cells ± GLPG1790 (lower panel). Results represent the mean value of four independent experiments. b Cell lysates from RD and
TE671 cells ± GLPG1790 at the indicated times were analysed by immunoblotting with specific antibodies for indicated proteins; α-Tubulin expression
shows the loading of samples. Representative of three independent experiments. c Immunofluorescence experiments showing the expression and
localization of CycD1 and p21 at 72 h after DMSO (−) or GLPG1790 (+) treatment. Representative images captured under ApoTome microscope at
40x magnification
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(Fig. 5f ) were also evident in the SC-GLPG1790 vs. SC-
DMSO comparisons. Taken together, these results sug-
gest that the inhibition of EPH signalling activates a
sustained myogenic program in ERMS cells by inducing
the sequential expression of myogenic genes and by
concomitantly counteracting the ERMS stem-like cell
phenotype.
GLPG1790 radiosensitizes ERMS cells by impairing the
DNA double-strand break repair
We assessed whether GLPG1790 may sensitize ERMS
cells to ionizing radiations by altering DNA damage and/
or impairing the molecular mechanisms of DSB (double-
strand break) repair. For this purpose, ERMS cells were
pretreated or not with GLPG1790 for 24 h and then
a b
c d
Fig. 4 GLPG1790 decreases wound closure and anchorage-dependent or -independent clonogenic ability of ERMS cells. RD and TE671 cells untreated
(DMSO) or treated with GLPG1790 were seeded at low concentration in a anchorage-dependent conditions or b anchorage-independent conditions.
Colonies were photographed and counted after 8 days of treatment. Results represent the mean values ± SD of three independent experiments. Statistical
significance: *p < 0.05 and ***p < 0.001 compared with the respective control (DMSO), arbitrarily set at 1. c Wound healing experiments in RD and TE671
cells. A scratch was made at time 0 and maintained for 24 h in the presence of GLPG1790 or DMSO. The dotted lines represent the edges of the wound.
Photographs were taken under light microscope (10x magnification). The migration index was plotted in bar graphs. Statistical significance: **p < 0.01
compared with the respective control (DMSO), arbitrarily set at 1. d Cell lysates from RD and TE671 cells treated with or without GLPG1790 for the
indicated hours were analysed by immunoblotting with specific antibodies against integrin αV, integrin β1, integrin β3 and integrin β5; α-Tubulin
expression shows the loading of samples. Representative of three independent experiments
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irradiated with a single dose of 4 Gy; after radiation treat-
ment, GLPG1790 was washed out and colony formation
assays were performed. As shown in Fig. 6a, GLPG1790
pretreatment significantly reduced ERMS ability to form
colonies with a 85.9 ± 4.4% inhibition in RD and
84.6 ± 1.1% in TE671. Concentration of γ-H2AX, a bio-
marker of DNA DSBs, and activation status and/or expres-
sion levels of ATM and DNA-PKcs, which govern the DSB
repair machinery, were determined in cell lysates obtained
after 2 h of a single dose of 4 Gy irradiation ± GLPG1790
(Fig. 6b). In the presence of GLPG1790 pretreatment for
24 h, γ-H2AX expression and phosphorylation levels of
ATM at Serine 1981 did not increase with ionizing radia-
tions in both cell lines (Fig. 6b). DNA-PKcs activation sta-
tus (phosphorylation of Threonine 2609) was counteracted
only in RD cells (Fig. 6b). These findings indicate that the
inhibition of the EPH signalling in ERMS cells reduces
H2AX accumulation and downstream DSB repair network.
a b
c d
e f
Fig. 5 GLPG1790 triggers myogenic differentiation and counteracts ERMS stem-like phenotype. a Cell lysates from RD and TE671 cells untreated (DMSO)
(−) or treated (+) with GLPG1790 for indicated times were analysed by immunoblotting with specific antibodies for indicated proteins; α-Tubulin expression
shows the loading of samples. Representative of three independent experiments. b Immunofluorescence experiments showing the expression of MYOD1
and MyHC, at 72 h after GLPG1790 treatment. Images captured under ApoTome microscope at 40× magnification. c Representative microphotographs of
RD and TE671 cells in adherent conditions (Adherent) and in stem cell (SC) medium after 15 days of incubation in the absence (SC-DMSO) or in the
presence of 3.5 μM GLPG1790 (SC-GLPG1790). d Histograms of percentage of CD133 positive cells determined by FACS analysis. Results represent the
mean values ± SD of four independent experiments. Statistical significance: **p < 0.01, ***p < 0.001 vs. Adherent, $$$p < 0.001 vs. SC-DMSO. e Histograms of
percentage of CXCR4 positive cells determined by FACS analysis. Results represent the mean value of four independent experiments ± SD. Statistical signifi-
cance: **p < 0.01, ***p < 0.001 vs. Adherent, $$p < 0.01 vs. SC-DMSO. fWestern blot analysis of Nanog in protein lysates from RD and TE671 cells in adher-
ent, SC-DMSO or SC-GLPG1790 cultured conditions for 15 days; α-Tubulin expression shows equal loading of samples. Representative of three
independent experiments
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GLPG1790 effects on signal transduction in ERMS cells
In order to correlate the effects of GLPG1790 on the
ERMS phenotype with specific biochemical mechanisms,
we investigated the activity of this compound on key sig-
nal transduction pathways linked to RMS development,
muscle differentiation and EPH signalling. To this pur-
pose, ERMS were treated with GLPG1790 at different
times and Western blot analysis was performed. As
shown in Fig. 6c, GLPG1790 treatment (i) rapidly and
persistently inhibited the phosphorylation/activation of
a
c
b
Fig. 6 GLPG1790 radiosensitizes ERMS cell lines and modulates signal transduction pathways. RD and TE671 cells untreated or pretreated with
GLPG1790 for 24 h were exposed or not to 4 Gy radiation treatment (RT). Two hours after RT, cells were seeded at low concentration for colony assays
or lysed for total protein extraction. a Representative pictures of colonies stained with crystal violet after 14 days of GLPG(−)/RT(−), GLPG(−)/RT(+) or
GLPG(+)/RT(+) treatments (Upper Panel). Colony forming efficiency was calculated by crystal violet absorbance (Lower Panel). Results represent the
mean values ± SD of three independent experiments. Statistical significance: ***p < 0.001 vs. GLPG(−)/RT(−), arbitrarily set at 1; $$$p < 0.001 vs.
GLPG(−)/RT(+). b Cell lysates from RD and TE671 cells were analysed by immunoblotting with specific antibodies for indicated proteins; α-Tubulin ex-
pression shows the loading of samples. Representative of three independent experiments. c Cell lysates from RD and TE671 treated ± 3.5 μM
GLPG1790 for different times were analysed by immunoblotting with specific antibodies for indicated proteins; α-Tubulin expression shows the loading
of samples. Representative of three independent experiments
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ERKs, AKTs, mTOR and Src proteins, (ii) induced the
rapid and persistent phosphorylation/activation of p38
in both RD and TE671 cell lines and (iii) was able to
activate JNKs transiently in RD (from 3 to 12 h) and
persistently in TE671 (from 3 to 72 h) cells.
Silencing EPH-A2 and/or EPH-B2 reproduces GLPG1790-
induced effects in ERMS cells
To investigate if the GLPG1790-mediated effects in RD
and TE671 cells were due to the suppression of EPH-A2
and/or EPH-B2 activity, we used specific small interfering
RNAs (siRNAs) directed against the EPH-A2 or EPH-B2
subtypes, which share the highest biochemical selectivity
profile versus GLPG1790 [21]. A sequence against the C.
elegans (CTRsiRNA) was used as a negative control. West-
ern blotting analysis at 72 h after transfection revealed
that EPH-A2 protein levels were specifically reduced in
EPH-A2siRNA-transfected cells (Fig. 7a), whilst EPH-B2
knockdown was obtained only in EPH-B2siRNA-transfected
samples (Fig. 7a). A significant reduction of both proteins
was observed in EPH-A2siRNA/EPH-B2siRNA cells com-
pared to those transfected with the negative control
siRNA (CTRsiRNA) (Fig. 7a). GLPG1790 did not perturbate
total levels of both EPH-A2 and EPH-B2 proteins (Fig. 7a).
At 72 h subsequent to transfection, direct counting for liv-
ing cells using trypan blue dye exclusion test confirmed
that EPH-A2, EPH-B2 and EPH-A2 + EPH-B2 depletion
could significantly inhibit the proliferation potential of
ERMS cells compared to CTRsiRNA cells (Fig. 7b). EPH-A2
silencing inhibited proliferation by 22% in RD and 24% in
TE617 cells, EPH-B2 silencing by 24% in RD and 36% in
TE671 whilst knocking down of both EPH-A2 and EPH-
B2 was able to reduce cell number by 63% in RD and 44%
in TE617 cells (Fig. 7b). To further determine whether the
reduced ERMS cell growth was due to alterations in cell
cycle progression, flow cytometry analysis was performed.
Based on PI staining of cellular DNA content, EPH-A2 or
EPH-B2 downregulation resulted in a significant
GLPG1790-like increase of cell percentage in G1 phase
with a concomitant decrease of cell percentage in S and
G2 phases (Silencing EPH-A2-RD; G1 69.32 ± 1.9%, S
23.47 ± 2.4%, G2 7.2 ± 0.32%, Silencing EPH-B2-RD; G1
73.13 ± 3.6%, S 18.66 ± 1.5%, G2 8.2 ± 0.29%, Silencing
EPH-A2-TE671; G1 66.54 ± 2.8%, S25.25 ± 1.5%, G2
8.2 ± 0.27%, Silencing EPH-B2-TE671; G1 67.32 ± 2.3%, S
26.45 ± 2.3%, G2 6.23 ± 0.17%), whilst CTRsiRNA-trans-
fected cells rapidly divided and progressed through the
cell cycle at high rates (RD G1 52.81 ± 2.5%, S
32.75 ± 2.3%, G2 13.44 ± 1.1%, TE671 G1 49.21.81 ± 1.4%,
S 36.57 ± 2.4%, G2 14.22 ± 1.5%,) (Fig. 7c, upper panel).
The concomitant silencing of EPH-A2 and EPH-B2 pro-
duced the most prominent effects (Silencing EPH-A2 +
EPH-B2-RD G1 76.0 ± 3.2%, S 16.21 ± 2.2%, G2
7.47 ± 0.31%, Silencing EPH-A2 + EPH-B2-TE671 G1
64.21 ± 7.8%, S 28.58 ± 4.5%, G2 7.12 ± 0.42%) although
the percentage of cells in the different phases did not
completely matched with the number obtained by 3.5 μM
GLPG1790 treatment (Fig. 7c, upper panel). Consistent
with G1 arrest, the expression of different cell cycle regu-
lators was modulated in a GLPG1790-related manner. As
GLPG1790, the expression of Cyclin A was significantly
downregulated by EPH-A2siRNA, EPH-B2 siRNA or EPH-
A2siRNA/EPH-B2siRNA in both the cell lines (Fig. 7c, lower
panel). As GLPG1790, the expression of the cell cycle in-
hibitor p21 was increased by EPH-A2 and EPH-A2/EPH-
B2 silencing in both cell lines, whilst EPH-B2 had effect
only in RD but not in TE671 cells (Fig. 7c, lower panel).
The expression of the cell cycle inhibitor p27 was signifi-
cantly increased by EPH-B2 and EPH-A2/EPH-B2 knock-
ing down mainly in TE671 cells (Fig. 7c, lower panel).
Heavy chain of sarcomeric myosin (MyHC) was increased
in a GLPG1790-like manner only in the presence of EPH-
A2 and EPH-B2 siRNA double transfection in both cell
lines (Fig. 7c, lower panel). The effects of EPH-A2siRNA,
EPH-B2 siRNA or EPH-A2siRNA/EPH-B2siRNA transfection
in ERMS oncogenic signalling were also investigated
(Fig. 7d). In a GLPG1790-like manner, (i) silencing of
EPH-A2 and EPH-A2/EPH-B2 affected ERK phosphoryl-
ation/activation in both RD and TE671 cell lines, whilst
EPH-B2siRNA reduced ERK activity only in TE671(Fig. 7d);
(ii) silencing of EPH-B2 and EPH-A2/EPH-B2 upregulated
p38 phosphorylation/activation in both ERMS cell lines,
whilst no effects on p38 phosphorylation/activation were
observed by EPH-A2 silencing (Fig. 7d); (iii) phosphoryl-
ation/activation status of JNKs was not affected by EPH-
B2 and/or EPH-B2 knocking down; (iv) transient deple-
tion of EPH-A2, EPH-B2 and EPH-A2/EPH-B2 expression
was able to downregulate AKT and Src phosphorylation in
both RD and TE671 cells (Fig. 7d). Concerning the pos-
sible role of EPH-A2 and/or EPH-B2 in radiosensitizing
ERMS cells, no significant effect was observed in EPH-
A2siRNA or EPH-B2 siRNA ERMS cells treated with 4 Gy of
RT (Fig. 7e), whilst silencing of both EPH-A2 and EPH-B2
radiosensitized ERMs cells but at a lesser extent than
GLPG1790 exposure (Fig. 7e). Taken together, the cellular
and molecular effects achieved by using EPH-A2 and
EPH-B2 siRNA combined knockdown are comparable to
GLPG1790 effects.
GLPG1790 inhibits tumour growth and radiosensitizes
ERMS in xenograft mouse models
For in vivo experiments, TE671 cell line was chosen due
to its intrinsic radioresistance in comparisons with the
other tumour cells [30]. When tumour volume reached
0.5–1.0 cm3 (T0), GLPG1790 (30 mg/kg) or vehicle
(0.5% methylcellulose) were administered by oral gavage
5 days a week for 2 weeks. RT treatment (2 Gy) was per-
formed after the administration of GLPG1790, on
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Fig. 7 EPH-A2 and EPH-B2 knocking down by RNA interfering affects ERMS cell viability, cell cycle distribution, activation of signal transduction
pathways and radiosensitivity. a EPH-A2 and EPH-B2 protein expression levels measured by Western blotting at 72 h in RD and TE671 cells after
EPH-A2 (EPH-A2siRNA) and/or EPH-B2 (EPH-B2siRNA) silencing in comparison to samples transfected with non-targeting control siRNA (CTRsiRNA),
arbitrarily set at 1. Images show representative Western blots of three independent experiments; α-Tubulin was used as loading control. b Viability
of RD and TE671 cells 72 h post-transfection with EPH-A2 and/or EPH-B2 siRNAs was calculated with respect to control cells (CTRsiRNA) by using
trypan blue exclusion staining. Results represent the mean value of three independent experiments ± SD. Statistical significance: *p <
0.05, **p < 0.01, ***p < 0.001 vs CTRsiRNA, $$$p < 0.001 vs EPH-A2siRNA, ###p < 0.001 vs EPH-B2siRNA. c FACS analysis performed on ERMS cells si-
lenced with EPH-A2, EPH-B2 or CTR siRNAs. Histograms show the distribution of cell populations in each phase of the cell cycle. Results represent
the mean values of three independent experiments (upper panel). Cell lysates were analysed by immunoblotting with specific antibodies for indi-
cated proteins; α-Tubulin expression shows the loading of samples. Representative of three independent experiments (lower panel). d Cell lysates
from RD and TE671 cells were analysed by immunoblotting with specific antibodies for indicated proteins; α-Tubulin was used as loading control.
Representative of three independent experiments. e Representative pictures of colonies stained with crystal violet at 14 days after irradiation (RT)
of ERMS cells transfected with EPH-A2siRNA, EPH-B2siRNA, CTRsiRNA or treated with 3.5 μM GLPG1790 (upper panel). Colony formation efficiency was
calculated by crystal violet absorbance. Results represent the mean values ± SD of three independent experiments. Statistical significance:
*p < 0.05, **p < 0.01, ***p < 0.001 vs. CTRsiRNA arbitrarily set at 1 (lower panel)
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alternate days, for 2 weeks and for a total of six applica-
tions. Tumour volumes were measured every 4 days for
a period of 24 days in untreated (vehicle), GLPG1790-
treated (GLPG1790), irradiated (RT) and GLPG1790/ir-
radiated (GLPG1790 + RT) tumours (Fig. 8a). The rate
of tumour growth was found to be markedly reduced by
GLPG1790 treatment, with a 71% reduction in tumour
growth being observed at the end of treatment
(P < 0.001; Fig. 8a). Furthermore, GLPG1790 + RT com-
bined treatment decreased growth by 83% versus RT
alone at end point (Fig. 8a). Tumour weights in mice
treated with GLPG1790 decreased significantly ranging
from 60 to 80% in GLPG1790(+)/RT(−) and from 80 to
90% in GLPG1790(+)/RT(+) in comparison to controls
(Fig. 8b). The number of mice with tumour progression
significantly differed across the groups, and this was
confirmed by the median values of TTP (Fig. 8c). In the
vehicle group, tumour progression occurred within
8 days after the beginning of treatment whilst in the RT
group, tumour progression occurred within 12 days after
a b
c d
Fig. 8 Effects of GLPG1790 combined or not with irradiation on in vivo tumour growth. a Growth curve of tumour volumes from xenografted
TE671 cell lines, untreated (vehicle), GLPG1790-treated (GLPG1790), irradiated (RT), GLPG1790-pretreated and irradiated (RT + GLPG1790). Tumour
volumes were evaluated as describes in methods and represent the mean ± SEM of 10 mice. The upper panel shows the sequential treatments
of xenografted mice started when tumours reached a volume of approximate 0.5 cm3. GLPG1790 (30 mg/kg) was administered 5 days a week for
2 weeks and before each irradiation, administered on alternate days. b Tumour weights in mice untreated or treated with GLPG1790, radiotherapy
or combined treatment. c Kaplan-Meier estimates for rates of progression for untreated (vehicle), GLPG1790, RT, or GLPG1790 + RT combination
in TE671-derived tumours. d Phosphorylation/activation status of EPH-A2, EPH-B, ERKs, AKTs and levels of Ki-67 protein in tumours from vehicle,
RT, GLPG1790, or GLPG1790 + RT-treated mice (a, b). Representative Western blot experiment of the 10 tumours analysed. Total EPH-A2, EPH-B,
ERKs, AKTs and α-Tubulin immunoblotting were used as loading control (lower panel)
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the beginning of irradiation treatment. The treatment
with GLPG1790 significantly improved the TTP com-
pared to vehicle (p < 0.0001) or RT (p < 0.0001). In the
GLPG1790 group, tumour progression occurred from
the 16th day after the beginning of treatment and com-
pleted within the day 24. The most evident improvement
was documented when GLPG1790 was coupled with RT:
in this group, no tumour progression occurred after the
beginning of treatments. Immunoblotting on excised
tumours showed that GLPG1790 treatment, combined
or not with RT, downregulated EPH-A2, EPH-B, ERK
and AKT phosphorylation and reduced Ki-67 expression
compared with tumours from vehicle-treated mice
(Fig. 8d). Thus, xenografted human TE671-derived
tumours are still sensitive to GLPG1790 after 13 days of
treatment (Fig. 8d).
Discussion
GLPG1790 is a selective and potent pan-inhibitor of the
EPH receptors [21], which are overexpressed in many
malignancies [12–16] and which are often associated
with a poor clinical outcome [13] as well as with a resist-
ance to chemo- [31, 32] and radio-therapy [33–35]. The
present study has investigated, for the first time, the pos-
sible in vitro antitumour activity of GLPG1790 in ERMS
by dissecting the drug-mediated biological effects and
molecular mechanisms in RD and TE671 human ERMS
cell lines. GLPG1790 was able to decrease the phosphor-
ylation/activation levels of EPH-A2 and EPH-B recep-
tors, which are highly expressed and abnormally
activated in ERMS cells lines and tumour biopsies (Fig. 1
for EPH-A2 and [18] for EPH-B). The in vitro inhibition
of EPH signalling seems to be a crucial step in reverting
ERMS cancer phenotype towards skeletal muscle differ-
entiation, by restricting the expression of proliferative
markers and by upregulating the expression of myogenic
differentiation markers. Indeed, GLPG1790 treatment at
low concentrations (≤ 3.5 μM) induced a significant de-
crease in cell proliferation and viability, primarily associ-
ated with cell cycle arrest, this supporting a cytostatic
activity of the drug. Accumulation at G1 phase occurred
through several molecular mechanisms, including a sig-
nificant reduction of both Cyclin A and Cyclin B1 levels,
and a marked overexpression of p21 and p27 cell cycle
regulators. Furthermore, GLPG1790 exposure led to the
downregulation of Rb tumour suppressor, this impairing
the transcriptional expression of proliferative genes. The
incubation of RD and TE671 cells with GLPG1790 also
promoted dramatic morphological changes, with the ap-
pearance of more elongated and fused cellular bodies
that was consistent with the induction of the myogenic
program. In line with this observation, GLPG1790 in-
duced a significant up-regulation of MYOD1 and myo-
genin, followed by increased levels of MyHC protein, a
marker of terminal myogenic differentiation, in both
ERMS cell lines. The evidence that impairment of EPH-
A2 is linked to myogenesis is in accordance with a re-
port describing the role of EPH/Ephrin interactions in
regulating the myogenic program at the expense of self-
renewal [36, 37]. Contrarily to what expected, Cyclin D1
levels were rapidly and persistently increased by
GLPG1790 treatment in comparison to mocked control
cells. The upregulation and perinuclear accumulation of
Cyclin D1, confirmed by the immunofluorescence exper-
iments, appear to be an intriguing finding. Indeed, sub-
cellular localization of Cyclin D1 outside the nucleus has
been reported to correlate with a lower proliferative
index in different cancer types [38, 39], this suggesting
that the restriction of Cyclin D1 to the perinuclear re-
gion may allow the suppression of G1-S progression. On
the other hand, an early accumulation of both Cyclin D1
and D2 is required for the IGF1-mediated myoblast dif-
ferentiation [40], this supporting a role of specific Cyclin
D proteins in the cellular context of muscle terminal dif-
ferentiation. So, further experiments will be needed to
better understand the specific role of Cyclin D1 in the
GLPG1790-induced ERMS myogenic differentiation.
The biological mechanisms altered by GLPG1790 in-
clude the modulation of several signal transduction
pathways, which are involved in promoting oncogenic
transformation and progression in many types of tu-
mours, and which have been previously linked to EPH
RTKs [6–8]. In particular, in both ERMS cell lines,
GLPG1790 concomitantly reduced activation status of
AKT, mTOR, ERK, JNK and Src proteins, whose related
signalling are known to promote ERMS development
and to block terminal muscle differentiation [22, 23, 41–
44]. Notably, p38 phosphorylation levels were dramatic-
ally increased by GLPG1790 treatment, confirming the
key role of this mitogen-activated protein kinase in the
reactivation of the terminal differentiation program in
both RD and TE671 cells [22, 28, 41–44]. Our data also
suggest that the GLPG1790-mediated acquisition of the
myogenic-like phenotype and the enhanced expression
of specific myogenic genes, such as MYOD1, myogenin
and MyHC, seems to pass through the reduction of
DNMT3B protein levels, whose knockdown has recently
been shown to be a key event in reactivating the ERMS
terminal differentiation program [28]. According to our
recent report that shows how the MEK/ERK pathway
plays a prominent role in maintaining the stem-like
phenotype of ERMS cells [22], we found that GLPG1790
dramatically prevented rhabdosphere formation and
downregulated the expression of the stem cell markers
CD133, CXCR4 and Nanog. The finding that GLPG1790
treatment induces cell cycle alteration and commits
ERMS cells to myogenesis suggests that this compound
has a therapeutic potential as a differentiating agent in
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ERMS tumours. Differentiation therapy has been shown
to have a significant clinical antitumour activity in acute
promyelocytic leukemia, and promising preclinical activ-
ity in liposarcoma and osteosarcoma [45, 46], this outlin-
ing the importance to test the antitumour effects of this
EPH inhibitor in xenograft models [21]. We also found
that GLPG1790 exposure was able to significantly re-
duce the migratory as well as the clonogenic capacity of
RD and TE671 cells by altering the expression of specific
proteins, including members of the integrin superfamily,
this supporting the role of EPH signalling in regulating
the migratory behaviour and metastatic potential of can-
cer cells [6–8]. Combined siRNA knockdown of both
EPH-A2 and EPH-B2 genes, herein, shown and known
[18] to be overexpressed in ERMS tumours, replicated
many of the phenotypic effects observed in ERMS cells
after drug exposure, confirming that GLPG1790 activity
is mediated by the efficient impairment of EPH activity
[21]. Finally, our data underline the role of GLPG1790
exposure in potentiating the effects of radiotherapy,
which usually works by inducing DSBs as well as by
inhibiting the non-homologous end joining (NHEJ) and
the homologous recombination (HR) DNA repair path-
ways in exposed tumour cells [47]. Indeed, GLPG1790
enhanced radiosensitivity of ERMS cell lines, as demon-
strated by the clonogenic survival reduction of more
Fig. 9 GLPG1790 molecular working models. GLPG1790 inhibits EPH receptor activity and blocks both forward and revers Ephrin signals which,
synergistically or individually, support (i) activation of AKT/mTOR and MEK/ERK signalling that support proliferation and cancer stem cell
phenotype; (ii) inhibition of pro-apoptotic signal mediated by JNKs; (iii) pro-differentiating signal sustained by p38; (iv) activation of damaged
DNA repair molecular mechanisms; (v) motility and invasion abilities by sustaining the SRC-mediated integrin signals
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than 90%, altering the accumulation of DNA DSBs, as
confirmed by the impaired expression of the phosphory-
lated form of the H2AX histone [48]. Even if the rela-
tionship between EPH/Ephrin signalling, DSB repair
machinery and response to RT is still largely unknown; a
correlation between EPH overexpression and the acqui-
sition of a radioresistant phenotype has been reported in
other solid tumours [34, 35, 49, 50]. Here, we showed
that GLPG1790 abrogates the RT-induced ATM and
DNA-PKcs phosphorylation, whose activation is linked
to the HR and NHEJ pathways, respectively [47]. Aug-
mentation of radiation response by GLPG1790 treatment
was also confirmed by our preliminary in vivo experi-
ments, in which the combination therapy with GLPG1790
and fractionated radiation was significantly more effective
than the drug or the RT alone in reducing tumour masses.
The current treatment for patients with RMS is a combin-
ation of surgery, chemotherapy and/or radiotherapy. How-
ever, the development of resistance to chemotherapy and
radiotherapy is often a significant limiting factor, leading
to therapeutic failures and poor survival [5]. Since EPH
signalling seems to sustain the oncogenic and radioresis-
tant phenotype of ERMS by regulating several molecular
mechanisms [50] as schematized in Fig. 9, the combined
use of GLPG1790 and RT may represent an attractive
strategy to make clinical treatment of ERMS tumours
more effective. Further studies in ERMS animal models
will be necessary to assess if GLPG1790 has a significant
activity in preventing the in vivo radioresistance. Further-
more, since chemical inhibition of the DNA repair ma-
chinery has been proposed as a novel strategy for cancer
treatment, radiosensitizing effects conferred by GLPG1790
in ERMS cells may also open a new field of promising ap-
proaches in the treatment of other cancer types that over-
express EPH family members.
Conclusions
The results of this study demonstrate the preclinical in vitro
and in vivo antitumour activity of GLPG1790, a new potent
pan-inhibitor of EPH receptors, in human ERMS cells. In
particular, GLPG1790 induces G1-growth arrest and com-
mits ERMS cells towards skeletal muscle differentiation.
Drug treatment prevents rhabdosphere formation and
downregulates stem cell markers. GLPG1790 also radiosen-
sitizes ERMS cells by impairing the DNA double-strand
break repair pathway. Finally, RMS xenografts exhibited
greater sensitivity to the combined GLPG1790 and radio-
therapy treatment.
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